Efficient endogenous anti-aging supramolecular composition as well as preparation method and application thereof

By encapsulating PDRN and tetrapeptide-1 in supramolecular compositions of fish olepithic extract and caprylic/capric triglycerides, using microfluidic and high-pressure microjet technology, it is solved that it is difficult to regulate the skin in the prior art. The problem of mitochondrial function of cells achieves efficient skin antioxidant and delayed aging effects.

CN119033665AActive Publication Date: 2024-11-29SHANDONG FREDA BIOTECH CO LTD +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411200547.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-29
Estimated Expiration
2044-08-29

AI Technical Summary

Technical Problem

Existing anti-aging products are difficult to fundamentally regulate the mitochondrial function in skin cells and maintain the vitality of skin cells, resulting in the rate of skin aging greater than the rate of self-rebirth, and cannot effectively delay aging.

Method used

Fish ole lipid extract and caprylic/capric triglycerides are used as external components to wrap PDRN and tetrapeptide-1, and a highly efficient supramolecular composition is formed through microfluidic control technology and high-pressure microjet treatment to improve skin antioxidation Capacity and mitochondria free radical scavenging ability to maintain the youthful state of mitochondria function.

Benefits of technology

It significantly improves the skin's antioxidant ability and mitochondria free radical removal ability, delays the skin's endogenous aging process, improves the skin's self-repair ability, and has a more obvious and long-term anti-aging effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033665A_ABST
    Figure CN119033665A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of cosmetics, and particularly relates to an efficient endogenous anti-aging supramolecular composition as well as a preparation method and application thereof. The tetrapeptide-1 and the PDRN have a synergistic effect, so that the free radical scavenging capacity of mitochondria can be improved, meanwhile, the expression quantity of mtDNA of the mitochondria can be increased, oxidative stress injury of the mitochondria is reduced, and the functional young state of the mitochondria is maintained. The composition which is uniform and stable in particle size and better in transdermal property is obtained through common treatment of microfluidics and microjet, the composition is added to a skin care product and applied to skin, the mitochondrial function of skin cells can be stable, various physiological activities can be kept normal, and therefore skin aging caused by endogenous factors is delayed.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of cosmetics, and specifically relates to a highly effective endogenous anti-aging supramolecular composition and a preparation method and application thereof. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Most people will begin to show signs of aging at the age of 25, such as fine lines, sagging face, rough and dull skin, etc. This is because the body's skin's self-repair ability begins to weaken. As we age, we can no longer rely solely on our own skin repair system to maintain the dynamic balance of the skin. The aging rate of skin cells is much faster than the rate of cell self-regeneration. Therefore, in order to truly fight aging, we need to pay more attention to skin aging caused by endogenous cellular aging.

[0004] All physiological activities of skin cells require the participation of mitochondria. As energy factories, mitochondria synthesize ATP for skin cells and can maintain the dynamic balance of the number of free radicals in skin cells, thereby ensuring that all physiological activities of our skin can proceed normally. Normal mitochondria can ensure the efficient operation of the skin's self-repair system and maintain the youthfulness of the skin. However, with age and the influence of the external environment, mitochondria will age, resulting in a decrease in mitochondrial energy supply capacity and a decrease in free radical scavenging efficiency. The skin cell's own ATP flow will weaken, and the skin cell aging rate will be greater than the self-regeneration rate, which will cause wrinkles, fine lines, sagging skin and other aging phenomena.

[0005] The inventor discovered during his research that in the development of traditional anti-aging products, the priority is often to use active ingredients to inhibit the growth of free radicals that cause skin cell aging, promote stratum corneum metabolism, reduce fine lines, and produce collagen. This active ingredient is the anti-aging target of traditional anti-aging products; and if you want to achieve a better anti-aging effect, you need to consider whether the active ingredient has the ability to fundamentally regulate mitochondrial function, reduce mitochondrial damage, and maintain skin cell vitality. Therefore, at this stage, technicians are in urgent need of designing and preparing a product that can perform endogenous anti-aging on skin cells to obtain better endogenous anti-aging effects. Summary of the invention

[0006] In order to solve the deficiencies of the prior art, the purpose of the present invention is to provide a highly efficient endogenous anti-aging supramolecular composition and its preparation method and application. The present invention uses fish egg lipid extract and caprylic / capric triglyceride as external phase components to encapsulate the internal phase components PDRN and tetrapeptide-1. The synergistic effect between the components can not only improve the deep antioxidant capacity of the skin itself and the free radical scavenging ability of mitochondria, but also increase the expression of mitochondrial mtDNA, reduce mitochondrial oxidative stress damage, maintain the youthful state of mitochondrial function, and delay the endogenous aging process of the skin.

[0007] In order to achieve the above object, the present invention is implemented through the following technical solutions:

[0008] The first aspect of the present invention provides a highly effective endogenous anti-aging supramolecular composition, which comprises an external phase component and an internal phase component; the external phase component comprises fish egg lipid extract and caprylic / capric triglyceride; and the internal phase component comprises an aqueous solution of tetrapeptide-1 and PDRN.

[0009] Preferably, the mass ratio of the external phase component to the internal phase component is 3 to 5:1.

[0010] Preferably, the mass percentage concentration of the tetrapeptide-1 and PDRN in the aqueous solution is 0.5-2%.

[0011] Preferably, the molecular weight of the PDRN is 0.5-1.5 million.

[0012] Preferably, the mass ratio of the fish egg lipid extract to caprylic / capric triglyceride is 1:5-10; further preferably, the mass ratio of the fish egg lipid extract to caprylic / capric triglyceride is 1:7-9.

[0013] Further preferably, the fish roe lipid extract is the roe of salmon, sturgeon or flatfish; the specific extraction method is: mixing the fish roe with purified water, crushing by ultrasonication, treating with a high-pressure homogenizer, and collecting the bottom product after centrifugation, which is the fish roe lipid extract.

[0014] Further preferably, the pressure of the high-pressure homogenization is 5 to 60 MPa, the flow rate is 20 to 45 L / h, and the number of homogenization times is 1 to 3 times.

[0015] The second aspect of the present invention provides a method for preparing the above-mentioned high-efficiency endogenous anti-aging supramolecular composition, comprising the following steps:

[0016] S1, dissolving tetrapeptide-1 and PDRN in water, and then adjusting the pH value of the solution to obtain an internal phase component;

[0017] S2, mixing the fish egg lipid extract and caprylic / capric triglyceride to prepare an external phase component;

[0018] S3, contacting the external phase component with the internal phase component through microfluidic technology to form a composite;

[0019] S4. Processing the composition through high-pressure microfluidization to obtain a supramolecular composition.

[0020] Preferably, in step S1, the pH value is 4.7 to 7.2.

[0021] Preferably, in step S3, in the microfluidic technology, the flow rate of the external phase component is 3 to 8 mL / h, and the flow rate of the internal phase component is 0.5 to 1 mL / h.

[0022] Preferably, in step S4, during the high-pressure microfluidic treatment, the pressure is set to 15000-20000 psi, and the number of treatments is 3 to 5 times.

[0023] The third aspect of the present invention provides a composition, which comprises the highly effective endogenous anti-aging supramolecular composition described in the first aspect and a functional polypeptide.

[0024] Preferably, the functional polypeptide is selected from one or more of palmitoyl polypeptides, acetyl polypeptides, arginine / lysine polypeptides, decapeptide-4, hexapeptide-9, nonapeptide-1, and dipeptide diaminobutyryl benzylamide diacetate.

[0025] Preferably, the composition further comprises a moisturizer, an emulsifier, a preservative and water; further preferably, the moisturizer is selected from one or more of glycerol, propylene glycol, butylene glycol, hexylene glycol, hyaluronic acid, betaine and trehalose; the emulsifier is selected from one or more of glyceryl stearate, hydrogenated lecithin, polysorbate-80, polysorbate-20, sorbitan olivate, polyglyceryl-6 stearate and polyglyceryl-6 behenate; the preservative is selected from one or more of methylparaben, phenoxyethanol, parahydroxyacetophenone, sodium benzoate and potassium sorbate.

[0026] Preferably, the added amount of the high-efficiency endogenous anti-aging supramolecular composition in the composition is 0.001-3% by mass; the added amount of the functional polypeptide in the composition is 0.0001-1% by mass; the added amount of the moisturizer in the composition is 0.1-10% by mass; the added amount of the preservative in the composition is 0.001-2% by mass; and the added amount of the emulsifier in the composition is 0.001-5% by mass.

[0027] The fourth aspect of the present invention provides the use of the highly effective endogenous anti-aging supramolecular composition of the first aspect or the composition of the third aspect in the preparation of skin care products.

[0028] Preferably, the skin care product is an essence, lotion, skin care water, cream or facial mask.

[0029] Preferably, the skin care product has anti-photoaging, anti-oxidation, whitening, anti-wrinkle and anti-aging effects.

[0030] The beneficial effects achieved by one or more technical solutions of the present invention are as follows:

[0031] (1) The present invention provides a highly effective endogenous anti-aging supramolecular composition. The combined use of PDRN and tetrapeptide-1 can synergistically delay endogenous cellular aging, improve the skin's own antioxidant capacity, and improve the mitochondrial free radical scavenging ability. At the same time, it can increase the expression of mitochondrial mtDNA, reduce mitochondrial oxidative stress damage, maintain the youthful state of mitochondrial function, and delay the endogenous aging process of the skin.

[0032] (2) The present invention innovatively combines fluid chemistry with supramolecular chemistry, combines the external phase components with the internal phase components in the microfluidic channel to form a composite material, and after being treated with microfluidics, the obtained supramolecular composite material has good quality stability and uniform particle size.

[0033] (3) Compared with other skin care products, the skin care products prepared by the present invention and comprising the high-efficiency endogenous anti-aging composition can better maintain the youthfulness of skin cells, enhance the skin's self-repair ability, alleviate the aging of skin cells from an endogenous source, and have a more obvious and longer-lasting anti-aging effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0035] Figure 1 The sample prepared in Example 1 of the present invention;

[0036] Figure 2 This is a particle size distribution diagram of the sample prepared in Example 1 of the present invention;

[0037] Figure 3 The particle size variation diagram of the samples prepared in Example 1 and Comparative Examples 3 to 5 of the present invention;

[0038] Figure 4 This is a graph showing changes in the ROS content in cells of the present invention;

[0039] Figure 5 This is a graph showing changes in mtDNA expression in cells of the present invention;

[0040] Figure 6 This is a diagram showing changes in mitochondrial density in cells of the present invention. DETAILED DESCRIPTION

[0041] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0042] The first typical embodiment of the present invention provides a highly effective endogenous anti-aging supramolecular composition, which comprises an external phase component and an internal phase component; the external phase component comprises fish egg lipid extract and caprylic / capric triglyceride; and the internal phase component comprises an aqueous solution of tetrapeptide-1 and PDRN.

[0043] In one or more examples of this embodiment, the mass ratio of the external phase component to the internal phase component is 3 to 5:1.

[0044] In one or more examples of this embodiment, the mass percentage concentration of the tetrapeptide-1 and PDRN in the aqueous solution is 0.5-2%.

[0045] In one or more examples of this embodiment, the molecular weight of the PDRN is 0.5-1.5 million.

[0046] In one or more examples of this embodiment, the mass ratio of the fish egg lipid extract to caprylic / capric triglyceride is 1:5-10.

[0047] In one or more examples of this embodiment, the mass ratio of the fish egg lipid extract to caprylic / capric triglyceride is 1:7-9.

[0048] In one or more examples of this implementation mode, the fish egg lipid extract is the fish egg of salmon, sturgeon or flatfish; the specific extraction method is: mixing the fish eggs with purified water, crushing them by ultrasonication, treating them with a high-pressure homogenizer, and collecting the bottom product after centrifugation, which is the fish egg lipid extract.

[0049] In one or more examples of this implementation mode, the pressure of the high-pressure homogenization is 5 to 60 MPa, the flow rate is 20 to 45 L / h, and the number of homogenization times is 1 to 3 times.

[0050] A second typical embodiment of the present invention provides a method for preparing the above-mentioned high-efficiency endogenous anti-aging supramolecular composition, comprising the following steps:

[0051] S1, dissolving tetrapeptide-1 and PDRN in water, and then adjusting the pH value of the solution to obtain an internal phase component;

[0052] S2, mixing the fish egg lipid extract and caprylic / capric triglyceride to prepare an external phase component;

[0053] S3, contacting the external phase component with the internal phase component through microfluidic technology to form a composite;

[0054] S4. Processing the composition through high-pressure microfluidization to obtain a supramolecular composition.

[0055] In one or more examples of this implementation mode, in step S1, the pH value is 4.7 to 7.2.

[0056] In one or more examples of this embodiment, in step S3, in the microfluidic technology, the flow rate of the external phase component is 3 to 8 mL / h, and the flow rate of the internal phase component is 0.5 to 1 mL / h.

[0057] In one or more examples of this embodiment, in step S4, during the high-pressure microfluidic treatment, the pressure is set to 15,000-20,000 psi, and the number of treatments is 3 to 5 times.

[0058] A third typical embodiment of the present invention provides a composition, which comprises the highly effective endogenous anti-aging supramolecular composition and a functional polypeptide as described in the first aspect.

[0059] In one or more examples of this embodiment, the functional polypeptide is selected from one or more of palmitoyl polypeptides, acetyl polypeptides, arginine / lysine polypeptides, decapeptide-4, hexapeptide-9, nonapeptide-1, and dipeptide diaminobutyryl benzylamide diacetate.

[0060] In one or more examples of this embodiment, the composition further comprises a moisturizer, an emulsifier preservative and water; further preferably, the moisturizer is selected from one or more of glycerol, propylene glycol, butylene glycol, hexylene glycol, sodium hyaluronate, betaine, and trehalose; the emulsifier is selected from one or more of glyceryl stearate, hydrogenated lecithin, polysorbate-80, polysorbate-20, sorbitan olivate, polyglyceryl-6 stearate, and polyglyceryl-6 behenate; the preservative is selected from one or more of methylparaben, phenoxyethanol, parahydroxyacetophenone, sodium benzoate, and potassium sorbate.

[0061] In one or more examples of this embodiment, the amount of the high-efficiency endogenous anti-aging supramolecular composition added to the composition is 0.001-3% by mass; the amount of the functional polypeptide added to the composition is 0.0001-1% by mass; the amount of the moisturizer added to the composition is 0.1-10% by mass; the amount of the preservative added to the composition is 0.001-2% by mass; and the amount of the emulsifier added to the composition is 0.001-5% by mass.

[0062] A fourth typical embodiment of the present invention provides the use of the highly effective endogenous anti-aging supramolecular composition described in the first aspect or the composition described in the third aspect in the preparation of skin care products.

[0063] In one or more examples of this implementation mode, the skin care product is an essence, an emulsion, a skin care lotion, a cream or a facial mask.

[0064] In one or more examples of this embodiment, the skin care product has anti-photoaging, anti-oxidation, whitening, anti-wrinkle and anti-aging effects.

[0065] PDRN is widely used in various cosmetics as a component with high-efficiency anti-inflammatory, repair and anti-aging effects. Tetrapeptide-1 is a polypeptide that can stimulate fibroblast proliferation and promote the synthesis of extracellular matrix such as collagen. The inventors found that when PDRN and tetrapeptide-1 are used in combination at a certain ratio, in addition to improving skin fine lines and enhancing skin elasticity and other external anti-aging performances, it can also significantly improve the problems of skin fine lines, dullness and roughness caused by mitochondrial damage or dysfunction, and play a synergistic role in delaying endogenous aging. The synergistic effect of the two components can improve the skin's own antioxidant capacity, improve the free radical scavenging ability of mitochondria, and at the same time increase the expression of mitochondrial mtDNA, reduce mitochondrial oxidative stress damage, maintain the youthful state of mitochondrial function, and delay the endogenous aging process of the skin.

[0066] At the same time, in order to improve the transdermal absorbability of PDRN and tetrapeptide-1 and better play the role of maintaining mitochondrial function, the present invention uses fish egg lipid extract and caprylic / capric triglyceride as external phase components to encapsulate PDRN and tetrapeptide-1. As a lipid component of natural origin, fish egg lipid extract has higher compatibility with human skin and can better carry internal phase components into the deep layer of the skin.

[0067] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.

[0068] Example 1: This example provides a highly effective endogenous anti-aging supramolecular composition and a preparation method thereof

[0069] In this embodiment, 100 g of a highly effective endogenous anti-aging supramolecular composition was prepared, wherein the mass ratio of the external phase component to the internal phase component was 4:1, the mass ratio of the fish egg lipid extract to caprylic / capric triglyceride was 1:7, and the mass percentage concentration of tetrapeptide-1 and PDRN in the aqueous solution was 0.5%.

[0070] The specific components and contents involved are:

[0071] The external phase components total 80g, including 10g of fish egg lipid extract and 70g of caprylic / capric triglyceride;

[0072] The internal phase components total 20g.

[0073] The specific preparation method comprises the following steps:

[0074] (1) Weigh 0.1 g of tetrapeptide-1 and PDRN respectively and dissolve them in water, add water to a total weight of 20 g, and adjust the pH to 6 to obtain an internal phase component;

[0075] (2) mixing 10 g of fish egg lipid extract and 70 g of caprylic / capric triglyceride to obtain an external phase component;

[0076] (3) injecting the external phase component and the internal phase component into the microfluidic channel, wherein the flow rate of the external phase component is 5 mL / h and the flow rate of the internal phase component is 0.5 mL / h;

[0077] (4) The composition of step (3) is subjected to microfluidization treatment at a pressure of 18000 psi for 3 times. Application Example 1: This application example provides a method for preparing a skin care water containing a highly effective endogenous anti-aging supramolecular composition.

[0078] The specific preparation method comprises the following steps:

[0079] (1) Preheat phase C and phase E to 35°C, stir until completely dissolved, and keep warm for later use;

[0080] (2) Heat the components of phase D to 35°C, sonicate until completely dissolved, and keep warm for later use;

[0081] (3) Heat all components of phase A to 35°C, stir until completely dissolved, add phase B and keep warm for later use;

[0082] (4) adding the liquid from step (3) to the liquid from step (2), stirring for 5-8 minutes, and shearing for 1-2 minutes;

[0083] (5) Add pre-dissolved phase C and phase E, stir well and serve.

[0084] The skin care water specifically includes the components as shown in Table 1:

[0085] Table 1 Components of skin care water containing high-efficiency endogenous anti-aging supramolecular composition

[0086]

[0087]

[0088] Comparative Example 1:

[0089] The difference from Example 1 is that tetrapeptide-1 is not added in step (1), and the other components and preparation methods are the same. Comparative Example 2:

[0090] The difference from Example 1 is that PDRN is not added in step (1), and the other components and preparation methods are the same.

[0091] The difference from Example 1 is that in step (3), the external phase component and the internal phase component are directly mixed and then stirred evenly, and the other components and preparation methods are the same.

[0092] Comparative Example 4:

[0093] The difference from Example 1 is that the microfluidization treatment method is not used in step (4), that is, the preparation method does not include step (4), and the other components and preparation methods are the same.

[0094] Comparative Example 5:

[0095] The difference from Example 1 is that in step (3), the external phase component and the internal phase component are directly mixed and then subjected to microfluidization treatment.

[0096] Comparative Example 6:

[0097] The difference from Application Example 1 is that the other components and addition amounts remain unchanged, the E phase component is changed to the composition prepared in Comparative Example 3, and the preparation method remains unchanged.

[0098] Comparative Example 7:

[0099] The difference from Application Example 1 is that the E phase component is not added, and the other components, addition amounts and preparation methods remain unchanged.

[0100] Experimental Example 1:

[0101] In this experimental example, a laser particle size analyzer was used to detect the particle size and polydispersity index (PDI) of Example 1 of the present invention and Comparative Examples 3 to 5. The results are shown in Table 2. The appearance and particle size of Example 1 are shown in Table 2. Figure 1-2 shown.

[0102] Table 2 Particle size and PDI test results of Example 1 and Comparative Examples 3 to 5

[0103]

[0104] At the same time, stability tests were conducted on Example 1 of the present invention and Comparative Examples 3 to 5. The above four groups of samples were placed at 45°C and the particle size changes of the system were measured on the day of preparation, 1 month and 3 months respectively. The results are shown in Table 3 and Figure 3 shown.

[0105] Table 3 Particle size change results

[0106]

[0107] It can be seen from the results in Table 2 and Table 3 that, compared with Example 1, Comparative Example 3 cannot obtain a transparent liquid when the amount of components added is the same, and the particle size and PDI values ​​of the system are greater than those of other systems. After 3 months of placement, the particle size changes from 310 nm to 786 nm, and the particle size change is the most obvious, indicating that the particle size of the composition system obtained by simple physical mixing is uneven and the stability is poor; compared with Comparative Examples 4 to 5, Example 1 has the smallest particle size and a more uniform distribution under the condition of the same component content. After 3 months of placement, the particle size changes very little, indicating that microfluidics and microjet co-treatment is conducive to obtaining a supramolecular composition with good stability, small particle size and uniform distribution.

[0108] Experimental Example 2:

[0109] Cellular reactive oxygen species (ROS) reflect the state of mitochondria to a certain extent. When mitochondrial function is in a normal state, the ROS content is in a dynamic balance and does not fluctuate significantly. When mitochondrial function is damaged, the ROS content in the cell will surge, causing damage to the cell and accelerating aging.

[0110] Experimental process: According to the literature and related data reports, human fibroblasts were selected to investigate the effects of Example 1 and Comparative Examples 1 to 5 on the content of cellular reactive oxygen species (ROS). The compositions obtained in Example 1 and Comparative Examples 1 to 5 were diluted to 10% (g / g, mass fraction) using serum-free DMEM medium, and after centrifugation, the supernatant was filtered using a 0.22 μm filter membrane to obtain 6 groups of sample mother solutions.

[0111] In this experiment, 21st generation fibroblasts were selected as the young group cell control, 54th generation as the aging group cell control, and 54th generation cells were treated with 2% sample mother solution as the sample group. Three parallels were set for each group. After culturing for 24 hours, DCFH-DA was added and continued to be cultured for 30 minutes. After excitation at 488nm on a multifunctional microplate reader, the fluorescence intensity of each well of the culture plate was detected at a wavelength of 525nm. The changes in ROS content of cells in each group are shown in Table 4 and Figure 4 shown.

[0112] Table 4 Results of changes in cell ROS content

[0113]

[0114]

[0115] Test results: According to Table 4, it can be seen that the ROS content of the aging group cells is significantly higher than that of the young group cells (about 1.85 times), indicating that the cell state is related to the ROS content, and normal mitochondrial function is conducive to maintaining the youthfulness of cells and delaying aging. After treating aging cells with Example 1, Comparative Example 1 and Comparative Example 2, the ROS content decreased. Among them, the ROS content of aging cells using Example 1 decreased most significantly, decreasing by 0.55, indicating that tetrapeptide-1 and PDRN have a synergistic effect on reducing the intracellular ROS content. The combined use of the two ingredients can significantly improve the antioxidant capacity of aging cells, maintain normal mitochondrial function, and play a highly efficient endogenous anti-aging role.

[0116] At the same time, compared with the senescent cell groups treated with Comparative Examples 3 to 5, the ROS content of the senescent cells treated with Example 1 decreased most significantly, by 0.55, indicating that the composition obtained by the combined treatment method of microfluidics and microjet in the present invention has the strongest ability to improve the antioxidant capacity of senescent cells and the best endogenous anti-aging effect.

[0117] Experimental Example 3:

[0118] When the mitochondrial function is damaged, it is easily affected by free radicals, resulting in oxidative stress, causing cell mtDNA damage and reduced expression. The present invention uses PCR-fluorescent probe method to examine the effects of Example 1 and Comparative Examples 1 to 5 on cell mtDNA expression.

[0119] Experimental process: The compositions obtained in Example 1 and Comparative Examples 1 to 5 were diluted to 10% (g / g, mass fraction) using serum-free DMEM medium. After centrifugation, the supernatant was filtered using a 0.22 μm filter membrane to obtain 6 groups of sample mother solutions.

[0120] In this experiment, 21st generation fibroblasts were selected as the young group cell control, and 54th generation cells were used as the aging group cell control. The 54th generation cells were treated with 2% sample mother solution as the sample group. After culturing for 24 hours, the supernatant was centrifuged. Subsequent incubation operations were performed according to the instructions of the mtDNA nucleic acid detection kit (Shanghai Bohu Biotechnology Co., Ltd.). After the incubation, the stop solution was added for 15 minutes, and the OD value of each well was detected at 450nm. The changes in the mtDNA expression of each group of cells are shown in Table 5 and Figure 5 shown.

[0121] Table 5 Results of changes in cell mtDNA expression

[0122] Group Relative mtDNA content Amount of improvement (compared to the aging group) Aging group 1 / Young Group 4 3 Example 1 3.2 2.2 Comparative Example 1 2.3 1.3 Comparative Example 2 1.9 0.9 Comparative Example 3 2.21 1.21 Comparative Example 4 2.05 1.05 Comparative Example 5 2.09 1.09

[0123] Test results: According to Table 5, it can be seen that the mtDNA expression of the young group cells is significantly higher than that of the aging group cells (about 4 times), indicating that the mtDNA expression is related to the cell state, and timely increasing the mtDNA expression of damaged cells is beneficial to delaying aging. After treating aging cells with Example 1, Comparative Example 1 and Comparative Example 2, the cell mtDNA expression was increased, but the mtDNA expression of aging cells using Example 1 was the most obvious, increasing by 2.2, indicating that tetrapeptide-1 and PDRN have a synergistic effect on increasing the cell mtDNA expression. The combined use of the two ingredients can significantly increase the cell mtDNA expression, which is beneficial to repair cells damaged by oxidative stress, maintain normal mitochondrial function, and play a role in efficient endogenous anti-aging.

[0124] At the same time, compared with the senescent cell groups treated with Comparative Examples 3 to 5, the mtDNA expression level of senescent cells treated with Example 1 was most significantly increased by 2.2, indicating that the composition obtained by the co-treatment method of microfluidics and microjet in the present invention has the strongest ability to increase the mtDNA expression level of senescent cells and has the best endogenous anti-aging effect.

[0125] Experimental Example 4:

[0126] In addition to examining the two indices that indirectly reflect mitochondrial function in Experimental Examples 2 and 3, the present invention also uses a cell permeable probe to directly measure the effects of Example 1 and Comparative Examples 1 to 5 on cell mitochondrial density.

[0127] Experimental process: The compositions obtained in Example 1 and Comparative Examples 1 to 5 were diluted to 10% (g / g, mass fraction) using serum-free DMEM medium. After centrifugation, the supernatant was filtered using a 0.22 μm filter membrane to obtain 6 groups of sample mother solutions.

[0128] In this experiment, the 21st generation fibroblasts were selected as the young group cell control, the 54th generation as the aging group cell control, and the 54th generation cells treated with 2% sample mother solution were used as the sample group. The selected fibroblasts were seeded in a 96-well culture plate at a density of 3×104 cells / well. After culturing for 24 hours, the samples were added and cultured for another 24 hours. PBS solution and Mitotracker Green probe were added to each well and placed at 37°C for 30 minutes. The cells were washed with PBS solution, and the fluorescence intensity of each well of the culture plate was detected at a wavelength of 516nm after excitation with the SpectraMAX molecular detection device at 490nm. The changes in the relative mitochondrial density of each group of cells are shown in Tables 6 and Figure 6 shown.

[0129] Table 6 Results of changes in relative mitochondrial density of cells

[0130] Group Relative mitochondrial density / % Improvement / % (compared to the aging group) Aging group 100 / Young Group 146 / Example 1 134 34 Comparative Example 1 112 12 Comparative Example 2 123 23 Comparative Example 3 119 19 Comparative Example 4 116 16 Comparative Example 5 113 13

[0131] Test results: According to Table 6, it can be seen that the mitochondrial density of the young group cells is significantly higher than that of the aging group cells (about 1.46 times), indicating that as the cells age, the mitochondrial density also decreases. The decrease in mitochondrial density causes insufficient cell energy supply and is unable to maintain various normal physiological activities of the cells. After treating aging cells with Example 1, Comparative Example 1 and Comparative Example 2, the cell mitochondrial density increased, but the mitochondrial density of aging cells using Example 1 increased most significantly, increasing by 34%, indicating that tetrapeptide-1 and PDRN have a synergistic effect on increasing cell mitochondrial density. The combined use of the two ingredients can significantly increase the cell mitochondrial density, which is beneficial to the activation of mitochondria, maintain the normal physiological activities of cells, slow down the loss of mitochondrial quantity caused by aging, and play a role in efficient endogenous anti-aging.

[0132] Compared with the senescent cell groups treated with Comparative Examples 3 to 5, the mitochondrial density of senescent cells treated with Example 1 was most significantly increased, by 34%, indicating that the composition obtained by the co-treatment method of microfluidics and microjet in the present invention is more conducive to the activation of mitochondria and has the best endogenous anti-aging effect.

[0133] Experimental Example 5:

[0134] This experimental example selects Application Example 1 and Comparative Examples 6-7 to conduct human anti-aging and firming efficacy tests.

[0135] Experimental process: This anti-wrinkle test was divided into 4 groups, each group consisted of 10 volunteers aged 35-55 years old with sagging facial skin and fine lines or wrinkles. Before the test, the same tester used the Visioline VL650 wrinkle tester to measure the facial skin wrinkle area of ​​the volunteers before the test, recorded as S0, and then the tester evenly applied 0.5g of the test sample to the facial skin of the volunteers twice a day (once in the morning and once in the evening). The blank group was smeared with an equal amount of pure water. The facial skin wrinkle area after continuous use for 0, 7, 14, 21, and 28 days was recorded, recorded as St, and the reduction in skin wrinkle area was calculated according to the following formula:

[0136] Skin wrinkle area reduction (%) = (St-S0) / S0*100%

[0137] According to the above test scheme, the test results are shown in Table 7.

[0138] Table 7 Skin wrinkle reduction results

[0139]

[0140] Analysis of the data in Table 7 shows that after using the skin care water containing the composition of Example 1, the wrinkle removal effect is more obvious, and the skin wrinkle area reduction can reach 50.5% in 28 days, while the skin care water containing the composition of Comparative Example 7 can reduce the skin wrinkle area reduction by 20.9% after 28 days, indicating that adding the composition prepared by the present invention into the skin care products can significantly improve the wrinkle removal and anti-aging effects of the skin care products. This is because the composition of the present invention can reduce mitochondrial oxidative stress damage, maintain the youthful state of mitochondrial function, and delay the endogenous aging process of the skin at the cellular level, so it has a better use effect;

[0141] Compared with the wrinkle-removing and anti-aging effects of the skin care water containing the composition of Example 1, the skin care water containing the composition of Comparative Example 6 can also reduce wrinkles, but the reduction in skin wrinkle area after 28 days is only 29.1%; at the same time, the efficiency of reducing the number of wrinkles by applying the skin care water containing Example 1 at 14 days, 21 days, and 28 days changes very little, which are 10.4%, 9.8%, and 6.9%, respectively, while the efficiency of applying the skin care water containing Comparative Example 6 is 5.8%, 4.1%, and 0.5%, respectively, which shows that even if the same components are added, the composition prepared by the present invention has better high-efficiency and long-lasting wrinkle-removing and anti-aging effects, further verifying that the preparation method using microfluidics and microjet of the present invention is effective, and the high-efficiency endogenous anti-aging composition with low particle size and high stability is more conducive to exerting its high-efficiency and long-lasting wrinkle-removing and anti-aging effects.

[0142] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A highly effective endogenous anti-aging supramolecular composition, It is characterized in that The supramolecular composition comprises an external phase component and an internal phase component; the external phase component is composed of fish egg lipid extract and caprylic / capric triglyceride; The internal phase component consists of an aqueous solution of tetrapeptide-1 and PDRN.

2. The supramolecular composition according to claim 1, It is characterized in that The mass ratio of the external phase component to the internal phase component is 3-5:1; the mass percentage concentration of the tetrapeptide-1 and PDRN in the aqueous solution is 0.5-2%; Wherein, the molecular weight of the PDRN is 0.5-1.5 million; the mass ratio of the fish egg lipid extract to caprylic acid / capric acid triglyceride is 1:5-10; preferably, the mass ratio of the fish egg lipid extract to caprylic acid / capric acid triglyceride is 1:7-9.

3. The supramolecular composition according to claim 2, It is characterized in that The fish egg lipid extract is the fish egg of salmon, sturgeon or flatfish; the specific extraction method is: mixing the fish eggs with purified water, crushing them by ultrasonication, treating them with a high-pressure homogenizer, and collecting the bottom product after centrifugation, which is the fish egg lipid extract; preferably, the pressure of the high-pressure homogenization is 5-60MPa, the flow rate is 20-45L / h, and the number of homogenization times is 1-3 times.

4. A method for preparing the highly effective endogenous anti-aging supramolecular composition according to claim 1, It is characterized in that The following steps are involved: S1, dissolving tetrapeptide-1 and PDRN in water, and then adjusting the pH value of the solution to obtain an internal phase component; S2, mixing the fish egg lipid extract and caprylic / capric triglyceride to prepare an external phase component; S3, contacting the external phase component with the internal phase component through microfluidic technology to form a composite; S4. Processing the composition through high-pressure microfluidization to obtain a supramolecular composition.

5. The preparation method according to claim 4, It is characterized in that In step S1, the pH value is 4.7-7.

2.

6. The preparation method according to claim 4, It is characterized in that In step S3, in the microfluidic technology, the flow rate of the external phase component is 3 to 8 mL / h, and the flow rate of the internal phase component is 0.5 to 1 mL / h; In step S4, during the high-pressure microfluidic treatment, the pressure is set to 15,000-20,000 psi, and the number of treatments is 3 to 5 times.

7. A composition, It is characterized in that The composition comprises the highly effective endogenous anti-aging supramolecular composition and a functional polypeptide as described in any one of claims 1 to 3; Preferably, the functional polypeptide is selected from one or more of palmitoyl polypeptides, acetyl polypeptides, arginine / lysine polypeptides, decapeptide-4, hexapeptide-9, nonapeptide-1, and dipeptide diaminobutyryl benzylamide diacetate.

8. The composition according to claim 7, It is characterized in that The composition also contains a moisturizer, an emulsifier, a preservative and water; further preferably, the moisturizer is selected from one or more of glycerol, propylene glycol, butylene glycol, hexylene glycol, sodium hyaluronate, betaine and trehalose; the emulsifier is selected from one or more of glyceryl stearate, hydrogenated lecithin, polysorbate-80, polysorbate-20, sorbitan olivate, polyglyceryl-6 stearate and polyglyceryl-6 behenate; the preservative is selected from one or more of methylparaben, phenoxyethanol, p-hydroxyacetophenone, sodium benzoate and potassium sorbate.

9. The composition according to any one of claims 7 to 8, It is characterized in that The added amount of the high-efficiency endogenous anti-aging supramolecular composition in the composition is 0.001-3% by mass; the added amount of the functional polypeptide in the composition is 0.0001-1% by mass; the added amount of the moisturizer in the composition is 0.1-10% by mass; the added amount of the preservative in the composition is 0.001-2% by mass; and the added amount of the emulsifier in the composition is 0.001-5% by mass.

10. Use of the highly effective endogenous anti-aging supramolecular composition according to any one of claims 1 to 3 or the composition according to claims 7 to 9 in the preparation of skin care products; Preferably, the skin care product is an essence, lotion, skin care water, cream or facial mask; Preferably, the skin care product has anti-photoaging, anti-oxidation, whitening, anti-wrinkle and anti-aging effects.

Citation Information

Patent Citations

  • PDRN-containing nano-emulsion and preparation method thereof

    CN115836982A

  • Multi-effect anti-aging co-delivery nano composition suitable for microneedle as well as preparation method and application of multi-effect anti-aging co-delivery nano composition

    CN116602884A

  • Smearing type wrinkle-removing composition and application thereof

    CN116942559A

  • Preparation method of self-assembled roe extract nano-liposome

    CN118490602A

  • Resin composition and display device using the same

    KR1020250144146A